Trial Profile
Abatacept to Silence Anti-citrullinated Protein Antibody-expressing B Cells in Rheumatoid Arthritis (ASCARA)
Status:
Completed
Phase of Trial:
Phase IV
Latest Information Update: 10 Jul 2023
Price :
$35
*
At a glance
- Drugs Abatacept (Primary) ; Methotrexate (Primary)
- Indications Rheumatoid arthritis
- Focus Biomarker; Pharmacodynamics
- Acronyms ASCARA
- 03 Jun 2023 Results (n=30) of phenotypic analysis presented at the 24th Annual Congress of the European League Against Rheumatism
- 05 Jun 2022 Status changed from active, no longer recruiting to completed.
- 17 Sep 2021 Planned End Date changed from 1 Oct 2022 to 1 May 2022.